Enanta Pharmaceuticals (ENTA) Other Working Capital Changes (2012 - 2026)

Enanta Pharmaceuticals has reported Other Working Capital Changes for 15 years, with the latest figure at $258000.0 in Q1 2026.

• For the quarter ending Q1 2026, Other Working Capital Changes fell 2.64% year-over-year to $258000.0; the trailing twelve-month figure through Mar 2026 stood at $258000.0 (down 2.64% YoY), and the FY2025 full-year result was $379000.0, up 187.73% from the prior year.
• Other Working Capital Changes for Q1 2026 stood at $258000.0, up from -$4.2 million in the prior quarter.
• The five-year high for Other Working Capital Changes was $4.1 million in Q2 2024, with the low at -$4.2 million in Q4 2025.
• Historically, Other Working Capital Changes has averaged -$281882.4 across 5 years, with a median of $109000.0 in 2023.
• The largest YoY upside for Other Working Capital Changes was 3692.66% in 2024 against a maximum downside of 9505.56% in 2024.
• Enanta Pharmaceuticals' Other Working Capital Changes stood at -$717000.0 in 2022, then soared by 97.49% to -$18000.0 in 2023, then sank by 9505.56% to -$1.7 million in 2024, then tumbled by 145.69% to -$4.2 million in 2025, then surged by 106.07% to $258000.0 in 2026.
• The last three Other Working Capital Changes figures came in at $258000.0 (Q1 2026), -$4.2 million (Q4 2025), and -$147000.0 (Q3 2025), per Business Quant data.